September 29, 2016 / 11:07 AM / a year ago

BRIEF-Maxigen Biotech gets marketing approval for Foramic Bone Graft Substitutes from CFDA

Sept 29 (Reuters) - Maxigen Biotech :

* Says it got marketing approval for its product Foramic Bone Graft Substitutes from CFDA (China Food and Drug Administration) on Sep. 29

Source text in Chinese: goo.gl/wiFdgh

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below